Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More

Addex Therapeutics Concludes Enrollment In Part 1 Of Phase 2 Study of ADX71149 For Epilepsy. Independent Interim Review Committee’s Outcome And Next Steps For The Program Are Expected By The End Of Q1 2023

The trial is being conducted by Janssen Pharmaceuticals Inc part of Johnson & Johnson. Based on the outcome of the review and recommendations from the IRC, Janssen will evaluate the next steps for

ADXN